The Pharma Letter1h
Plus Thera teams up with SpectronRx for radiotherapy production
Plus Therapeutics has partnered with SpectronRx for the production of Rhenium (186Re) obisbemeda, a targeted radiotherapy for ...
The Pharma Letter1h
Beam announces early-stage data on sickle cell disease therapy
Beam Therapeutics will present new data on its sickle cell disease (SCD) therapies at the ASH meeting, including results from ...
The Pharma Letter16h
Ring expands global R&D efforts with new Singapore partnerships
Massachusetts-based Ring Therapeutics has partnered with Singapore’s A*STAR and SERI to advance gene therapy using its ...
The Pharma Letter19h
AstraZeneca sees progress in obesity drug trials, highlights new oral option
AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...
The Pharma Letter18h
The Pharma Letter M&A roundup - October 2024
Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...
The Pharma Letter22h
Vertex ups guidance again as results exceed estimates
US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...
The Pharma Letter22h
PharmaMar gets $10 million milestone from Janssen for Yondelis
Spanish drugmaker PharmaMar Group today said it has received a payment of $10 million from Janssen Products, a Johnson & ...
The Pharma Letter12h
FDA approves REMS, advancing new drug disposal option for opioid analgesics
The US Food and Drug Administration (FDA) has announced approval of a modification to the Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS). With this approval, companies ...